Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report
Myeloid sarcomas (MS) are rare extramedullary manifestations of myeloid progenitor cells occurring with or without acute myeloid leukemia. Peritoneal MS is exceptionally uncommon, with no established treatment guidelines, but treatment has historically consisted of cytotoxic chemotherapy. We present...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048925000366 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849239385292144640 |
|---|---|
| author | Kavya Sudireddy Minorvi Amin Rafy Odeh Patrick Svrcek Salwa Khedr Lloyd Hutchinson Shyam A. Patel Jan Cerny Laurie Pearson |
| author_facet | Kavya Sudireddy Minorvi Amin Rafy Odeh Patrick Svrcek Salwa Khedr Lloyd Hutchinson Shyam A. Patel Jan Cerny Laurie Pearson |
| author_sort | Kavya Sudireddy |
| collection | DOAJ |
| description | Myeloid sarcomas (MS) are rare extramedullary manifestations of myeloid progenitor cells occurring with or without acute myeloid leukemia. Peritoneal MS is exceptionally uncommon, with no established treatment guidelines, but treatment has historically consisted of cytotoxic chemotherapy. We present the case of a 78-year-old female with 60% CD34+, HLA-DR+, and CD33+ myeloblasts in ascitic fluid, while bone marrow biopsy demonstrated only molecular evidence of the leukemic clone with FLT3-ITD, ASXL1, and TET2 mutations. Findings were consistent with primary peritoneal myeloid sarcoma. Due to chemotherapy ineligibility, the patient was treated with decitabine and venetoclax. After nine cycles, she demonstrated a complete radiographic response. To our knowledge, this is the first case report of a patient with primary peritoneal MS treated with a combination of a hypomethylating agent and venetoclax. |
| format | Article |
| id | doaj-art-8733a9d231024252b8cfd6ed452c3e8b |
| institution | Kabale University |
| issn | 2213-0489 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-8733a9d231024252b8cfd6ed452c3e8b2025-08-20T04:01:01ZengElsevierLeukemia Research Reports2213-04892025-01-012410053410.1016/j.lrr.2025.100534Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case reportKavya Sudireddy0Minorvi Amin1Rafy Odeh2Patrick Svrcek3Salwa Khedr4Lloyd Hutchinson5Shyam A. Patel6Jan Cerny7Laurie Pearson8Department of Medicine, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA; Corresponding author.Department of Neurology, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADepartment of Pathology, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADepartment of Radiology, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADepartment of Pathology, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADepartment of Pathology, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADivision of Hematology/Oncology, Department of Medicine, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADivision of Hematology/Oncology, Department of Medicine, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USADivision of Hematology/Oncology, Department of Medicine, UMass Chan Medical School, 55 Lake Avenue North, Worcester, MA 01655, USAMyeloid sarcomas (MS) are rare extramedullary manifestations of myeloid progenitor cells occurring with or without acute myeloid leukemia. Peritoneal MS is exceptionally uncommon, with no established treatment guidelines, but treatment has historically consisted of cytotoxic chemotherapy. We present the case of a 78-year-old female with 60% CD34+, HLA-DR+, and CD33+ myeloblasts in ascitic fluid, while bone marrow biopsy demonstrated only molecular evidence of the leukemic clone with FLT3-ITD, ASXL1, and TET2 mutations. Findings were consistent with primary peritoneal myeloid sarcoma. Due to chemotherapy ineligibility, the patient was treated with decitabine and venetoclax. After nine cycles, she demonstrated a complete radiographic response. To our knowledge, this is the first case report of a patient with primary peritoneal MS treated with a combination of a hypomethylating agent and venetoclax.http://www.sciencedirect.com/science/article/pii/S2213048925000366Peritoneal myeloid sarcomaExtramedullary AMLHypomethylating agentsVenetoclax |
| spellingShingle | Kavya Sudireddy Minorvi Amin Rafy Odeh Patrick Svrcek Salwa Khedr Lloyd Hutchinson Shyam A. Patel Jan Cerny Laurie Pearson Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report Leukemia Research Reports Peritoneal myeloid sarcoma Extramedullary AML Hypomethylating agents Venetoclax |
| title | Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report |
| title_full | Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report |
| title_fullStr | Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report |
| title_full_unstemmed | Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report |
| title_short | Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report |
| title_sort | effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax a case report |
| topic | Peritoneal myeloid sarcoma Extramedullary AML Hypomethylating agents Venetoclax |
| url | http://www.sciencedirect.com/science/article/pii/S2213048925000366 |
| work_keys_str_mv | AT kavyasudireddy effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT minorviamin effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT rafyodeh effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT patricksvrcek effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT salwakhedr effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT lloydhutchinson effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT shyamapatel effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT jancerny effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport AT lauriepearson effectivetreatmentofperitonealmyeloidsarcomawithdecitabineandvenetoclaxacasereport |